Erschienen in:
09.04.2022 | Letter to the Editor
Interactions with the CYP3A inhibitor voriconazole differ between extended-LCP- and immediate-release tacrolimus formulations
verfasst von:
Gerold Thölking, Ulrich Jehn, Stefan Reuter
Erschienen in:
International Journal of Hematology
|
Ausgabe 6/2022
Einloggen, um Zugang zu erhalten
Excerpt
We read with great interest the recent study by Nakashima et al. They report changes in tacrolimus (Tac) concentration-to-dose (C/D) ratio after discontinuation of letermovir [
1]. The authors studied 57 patients who underwent allogeneic hematopoietic cell transplantation (HCT). The participants received letermovir for prophylaxis against cytomegalovirus (CMV) infection and fluconazole or voriconazole against fungal infection. In the fluconazole group, discontinuation of letermovir resulted in a significant decrease in the Tac C/D ratio, whereas the Tac C/D ratio remained stable in the voriconazole group. The authors conclude that the potent CYP3A4-inhibitory effect of voriconazole has an overwhelming impact on Tac metabolism compared with the weak CYP3A4-inhibitory effect of fluconazole when letermovir is discontinued [
1]. …